Ann: AstraZeneca Partners LBT for APAS Pharma Development, page-10

It's a fair point and in times of tighter economic conditions perhaps offering the ability to utilise the machine without the initial capital outlay, would be a tempting proposition. However, that would mean LBT would have to bear the brunt of the capital outlay of the machines , unless they leased them, and I don't think the Company could support that right now. I do suspect that their larger partners must be thinking about having this kind of model though. And why not a blend if it gets customers on board and machines into labs increasing market presence